Celgene - Biomaterials Business' Unit Acquisition

Celgene - Biomaterials Business raised a round of funding on January 28, 2016. Investors include Human Longevity.

Orally administered, small molecule drugs for the treatment of cancer and immunological diseases. The key mechanisms of action for the Company's drugs are modulation of the overproduction of TNF - and…

Articles about Celgene - Biomaterials Business' Unit Acquisition: